Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medpace Holdings's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 51.82.
Medpace Holdings's Days Inventory for the
three
months ended in Jun. 2026 was 0.
Medpace Holdings's Days Payable for the
three
months ended in Jun. 2026 was 6.6.
Therefore, Medpace Holdings's Cash Conversion Cycle (CCC) for the
three
months ended in Jun. 2026 was 45.22.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Medpace Holdings Cash Conversion Cycle Related Terms
Medpace Holdings Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Medpace Holdings's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:MEDP vs ICLR, RVTY, CRL: Cash Conversion Cycle Comparison
For the Diagnostics & Research subindustry, Medpace Holdings's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings Cash Conversion Cycle vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Medpace Holdings's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings (MEX:MEDP) has a Cash Conversion Cycle of 45.22 as of Jun. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Medpace Holdings and its competitors.
Is Medpace Holdings' Cash Conversion Cycle too high?
Medpace Holdings' current Cash Conversion Cycle is 45.22. The Medical Diagnostics & Research industry median Cash Conversion Cycle is 74.74. Medpace Holdings' value of 45.22 is 39.5% below this industry median. Overall, Medpace Holdings has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' Cash Conversion Cycle compare to ICLR and RVTY?
Medpace Holdings' Cash Conversion Cycle of 45.22 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Cash Conversion Cycle is 74.74. Medpace Holdings' value of 45.22 is 39.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Diagnostics & Research company?
The median Cash Conversion Cycle among Medical Diagnostics & Research companies is 74.74, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medpace Holdings's current Cash Conversion Cycle of 45.22 is 39.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Medpace Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Cash Conversion Cycle is 74.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medpace Holdings's current Cash Conversion Cycle is 45.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Medpace Holdings (MEX:MEDP) has a current Cash Conversion Cycle of 45.22. The stock's GF Value™ is MXN6,131.53, compared to a current price of MXN7,022.03 — trading 14.5% above its estimated fair value. The current Cash Conversion Cycle is 45.22 and 39.5% below the Medical Diagnostics & Research industry median of 74.74. Medpace Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Medpace Holdings (MEX:MEDP), the current Cash Conversion Cycle is 45.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (MEX:MEDP) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of MXN7,022.03 is trading 14.5% above its estimated GF Value™ of MXN6,131.53.
Key valuation signals for MEX:MEDP:
Cash Conversion Cycle: 45.22
GF Value™: MXN6,131.53 vs. price of MXN7,022.03 (14.5% above fair value)
Industry Position: 39.5% below the Medical Diagnostics & Research median
No single metric tells the full story. See the MEX:MEDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
95GF Score
Get the complete analysis for MEX:MEDP
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MEDP has been successfully added to your 
